< 生产厂家价格 >

酒石酸卡巴拉汀

酒石酸卡巴拉汀用途

Rivastigmine酒石酸盐是胆碱酯酶抑制剂,IC50为5.5 uM,还能抑制丁酰胆碱酯酶和乙酰胆碱酯酶。

点击显示

酒石酸卡巴拉汀名称

[ CAS 号 ]:
129101-54-8

[ 中文名 ]:
酒石酸卡巴拉汀

[ 英文名 ]:
Rivastigmine (tartrate)

[中文别名 ]:

[英文别名 ]:

RivastigMine L-Tartrate
Rivastigmine Tartrate Salt
Rivastigmine
Rivastigmine Tartrate
Rivastigmine hydrogen tartrate
Rivastigmine (tartrate)

酒石酸卡巴拉汀生物活性

[ 描述 ]:

Rivastigmine酒石酸盐是胆碱酯酶抑制剂,IC50为5.5 uM,还能抑制丁酰胆碱酯酶和乙酰胆碱酯酶。

[ 相关类别 ]:

信号通路 >> 神经信号通路 >> 疼痛

研究领域 >> 神经疾病

[参考文献]

[1]. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract. 2009 May;63(5):799-805.

[2]. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther. 1998 Jul-Aug;20(4):634-47.

[3]. Stryjer R, Ophir D, Bar F et al. Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. Clin Neuropharmacol. 2012 Jul-Aug;35(4):161-4.

[4]. Han HJ, Lee JJ, Park SA et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease. J Clin Neurol. 2011 Sep;7(3):137-42.

[相关活性小分子]

酒石酸卡巴拉汀物理化学性质

[ 沸点 ]:
316.2ºC at 760 mmHg

[ 熔点 ]:
123-1250C

[ 分子式 ]:
C₁₈H₂₈N₂O₈

[ 分子量 ]:
400.423

[ 闪点 ]:
145ºC

[ 精确质量 ]:
400.184570

[ PSA ]:
147.84000

[ LogP ]:
0.63710

[ 外观性状 ]:
白色至灰白色粉末

[ 蒸汽压 ]:
0.000416mmHg at 25°C

[ 储存条件 ]:
-20°C Freezer

[ 水溶解性 ]:
可溶于：甲醇

酒石酸卡巴拉汀MSDS

详细MSDS(安全技术说明书)

酒石酸卡巴拉汀安全信息

[ 危害码 (欧洲) ]:
Xi

[ 安全声明 (欧洲) ]:
36

[ 危险品运输编码 ]:
NONH for all modes of transport

[ 海关编码 ]:
2942000000

酒石酸卡巴拉汀海关

[ 海关编码 ]: 2942000000

酒石酸卡巴拉汀文献

[Effect of AChE and BuChE inhibition by rivastigmin in a group of old-old elderly patients with cerebrovascular impairment (SIVD type)].

Minerva Med. 105(2) , 167-74, (2014)

Vascular dementia (VaD) is defined as a loss of cognitive function resulting from ischemic, hypoperfusive, or hemorrhagic brain lesions due to cerebrovascular disease or cardiovascular pathology. The ...

Blood pro-inflammatory cytokines in Alzheimer's disease in relation to the use of acetylcholinesterase inhibitors.

Int. J. Geriatr. Psychiatry 28(12) , 1312-7, (2013)

A potential anti-inflammatory role for acetylcholinesterase inhibitors (AChEIs) has been supported by animal studies. As very limited data exist from individuals with Alzheimer's disease (AD), the aim...

Rivastigmine for vascular cognitive impairment.

Cochrane Database Syst. Rev. 5 , CD004744, (2013)

Vascular dementia represents the second most common type of dementia after Alzheimer's disease. In older patients, in particular, the combination of vascular dementia and Alzheimer's disease is common...

更多文献